Date: 2016-09-15
Type of information: Development agreement
Compound: wearable device and machine learning platform
Company: Teva Pharmaceutical Industries (Israel) Intel (US - CA)
Therapeutic area: Genetic diseases - Neurodegenerative diseases - Rare diseases
Type agreement: development
Action mechanism: software platform
Disease: Huntington's disease
Details: * On September 15, 2016, Teva Pharmaceutical Industries announced a collaboration with Intel Corporation to develop a unique wearable device and machine learning platform for use in Huntington disease. This platform will continuously monitor and analyze key symptoms that impact daily living, in an effort to better understand disease progression and improve treatment evaluation.
Teva, working in collaboration with Intel , will deploy this novel technology platform for the first time in a sub-study within the ongoing Phase 2 Open-Pride HD Study. As part of this, patients will be asked to use a smartphone and wear a smartwatch equipped with sensing technology that will continuously measure their general functioning and movement. These data will be wirelessly streamed to a cloud-based platform specifically developed by Intel to analyze data from wearable devices. Proprietary algorithms will then translate these data, in near real-time, into objective scores of motor symptom severity. The study will start towards the end of the year and will take place in centers in the US and Canada .
This collaboration will leverage Intel's capabilities in analytics and algorithm development for movement detection, together with Teva's deep knowledge and experience in Huntington disease treatment and research.
This cloud-based solution for analyzing wearable device data is being developed using the open-source Intel Trusted Analytics Platform (TAP), a software platform optimized for performance and security to accelerate the creation of advanced analytics and machine learning solutions. Initial development was done in collaboration with The Michael J. Fox Foundation for use in Parkinson's disease research.
Financial terms:
Latest news:
